DividendChannel.com

Analysts Predict 25% Upside For IBBQ

By Dividend Channel Staff, Friday, February 2, 6:55 AM ET

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.83 per unit.

With IBBQ trading at a recent price near $22.23 per unit, that means that analysts see 25.18% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IBBQ's underlying holdings with notable upside to their analyst target prices are CureVac NV (NASDAQ:CVAC), Caribou Biosciences Inc (NASDAQ:CRBU), and HUTCHMED (China) Ltd (NASDAQ:HCM). Although CVAC has traded at a recent price of $3.58/share, the average analyst target is 342.74% higher at $15.85/share. Similarly, CRBU has 228.85% upside from the recent share price of $6.69 if the average analyst target price of $22.00/share is reached, and analysts on average are expecting HCM to reach a target price of $25.54/share, which is 97.53% above the recent price of $12.93. Below is a twelve month price history chart comparing the stock performance of CVAC, CRBU, and HCM:

CVAC, CRBU, and HCM Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
Invesco Nasdaq Biotechnology ETF IBBQ $22.23 $27.83 25.18%
CureVac NV CVAC $3.58 $15.85 342.74%
Caribou Biosciences Inc CRBU $6.69 $22.00 228.85%
HUTCHMED (China) Ltd HCM $12.93 $25.54 97.53%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on CVAC — FREE
Get the latest Zacks research report on CRBU — FREE
Get the latest Zacks research report on HCM — FREE


This Article's Word Cloud:   Analyst   Below   Biosciences   Biotechnology   CRBU   CVAC   Caribou   China   CureVac   ETFs   FREEGet   IBBQ   Invesco   Nasdaq   Target   Upside   With   Zacks   about   above   analyst   analysts   average   background   based   border   bottom   color   data   font   from   have   hctblstyle   holdings   implied   latest   mdash   month   padding   price   recent   report   research   share   target   targets   that   trading   underlying   upside

Analysts Predict 25% Upside For IBBQ | www.DividendChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in Dividend Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Dividend Channel; Meet Our Editorial Staff.